2716-99-6

Basic information

• Product Name: 2-Ethoxy-N-[2-(diethylamino)ethyl]-4-quinolinecarboxamide
• Synonyms: 2-Ethoxy-N-[2-(diethylamino)ethyl]-4-quinolinecarboxamide
• CAS NO: 2716-99-6
• Molecular Formula: C18H25N3O2
• Molecular Weight: 315.41
• Mol File: 2716-99-6.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 454.96°C (rough estimate)
• Appearance: /
• Density: 1.1345 (rough estimate)
• Refractive Index: 1.5855 (estimate)
• Water Solubility: 208.2mg/L(temperature not stated)
• CAS DataBase Reference: 2-Ethoxy-N-[2-(diethylamino)ethyl]-4-quinolinecarboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Ethoxy-N-[2-(diethylamino)ethyl]-4-quinolinecarboxamide(2716-99-6)
• EPA Substance Registry System: 2-Ethoxy-N-[2-(diethylamino)ethyl]-4-quinolinecarboxamide(2716-99-6)

Safety Data

• Hazardous Substances Data: 2716-99-6(Hazardous Substances Data)

Upstream product

• 5471-39-6 2-ethoxy-quinoline-4-carboxylic acid ethyl ester 
• 100-36-7 N,N-diethylethylenediamine 
• 87864-14-0 2-chloro-quinoline-4-carboxylic acid-(2-diethylamino-ethylamide) 
• 141-52-6 sodium ethanolate 
• 2388-32-1 2-chloroquinoline-4-carbonyl chloride 
• 64-17-5 ethanol 
• 5467-57-2 2-chloroquinoline-4-carboxylic acid 

Relevant articles and documents

Identification of dibucaine derivatives as novel potent enterovirus 2C helicase inhibitors: In vitro, in vivo, and combination therapy study

Enterovirus A71 (EV-A71) is a human pathogen causing hand, foot and mouth disease (HFMD) which seriously threatened the safety and lives of infants and young children. However, there are no licensed direct antiviral agents to cure the HFMD. In this study, a series of quinoline formamide analogues as effective enterovirus inhibitors were developed, subsequent systematic structure-activity relationship (SAR) studies demonstrated that these quinoline formamide analogues exhibited good potency to treat EV-A71 infection. As described, the most efficient EV-A71 inhibitor 6i showed good anti-EV-A71 activity (EC50 = 1.238 μM) in RD cells. Furthermore, compound 6i could effectively prevent death of virus infected mice at dose of 6 mg/kg. When combined with emetine (0.1 mg/kg), this treatment could completely prevent the clinical symptoms and death of virus infected mice. Mechanism study indicated that compound 6i inhibited EV-A71 via targeting 2C helicase, thus impeding RNA remodeling and metabolism. Taken together, these data indicated that 6i is a promising EV-A71 inhibitor and worth extensive preclinical investigation as a lead compound.